Mesoblast Ltd (MESO) stock

MESONasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends June 30Also trades as MEOBF

Financials through fiscal 2026, year ended Jun 30, 2026Last filing: 20-F on Aug 27, 2026Score 6/30

$13.27+0.17 (+1.30%)

Close on Nov 13, 2026Market cap $1.72BP/E –Yield –

Mesoblast ebitda

EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.

Mesoblast has not reported this figure in its SEC filings, or the share price needed to calculate it is not available yet.

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is MESO.

Revenue growth599.2% · median 79.6%

Gross margin86.1% · median 35.8%

Net margin-47.8% · median -186.4%

Advertisement
300 × 250

See a number that looks wrong?